Fractyl Health, Inc. GUTS

BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: On-demand

Fractyl Health (NASDAQ:GUTS) shares rose 2. 8% in pre-market trading ahead of the company’s Virtual Commercial Strategy Day, scheduled for 11:00 AM ET on Tuesday.

BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for Revita®. To register, click here. The event follows the Company

Moby summary of Fractyl Health, Inc. Common Stock's Q2 2026 earnings call

Fractyl Health Inc (GUTS) reports strong REMAIN-1 results, a clear regulatory path for Revita, and a cash runway into early 2027.

One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure REMAIN-1 Pivotal Cohort

BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the “Events” section of

BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: BTIG Virtual Biotechnology ConferenceFormat: One-on-one meetingsDates: July

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026 Company to host investor webcast today at 8:00 a.m. ET BURLINGTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Compan

Fractyl Health is under fresh scrutiny after analysts reset its fair value estimate from US$7.44 to US$5.03 per share, a shift that reframes expectations around the stock. The updated US$4 price target is being linked to the potential of Revita and the scale of the GLP-1 discontinuation funnel, with commentary weighing both clinical considerations and execution risk. As you read on, you will see how this evolving narrative is taking shape and what to watch if you are tracking Fractyl...

Fractyl Health Inc (NASDAQ:GUTS) is one of billionaire Lee Ainslie’s stocks with huge upside potential. The stock has gained roughly 18% over the past month, and analysts see it surging 530% over the next 12 months. On May 11, Fractyl Health Inc (NASDAQ:GUTS) announced that it has been cleared to go ahead with the planned […]

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure 5.3% mean weight change observed with Revita (n=15); published third-party studies after GLP-1 withdrawal alone have shown ~15% weight regain at similar time points 33% of patients continued to lose further weight one year after discontinuing a GLP-1 Next anticipated Revita® clinical data readouts are one-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026